Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

The Angels Initiative

Stroke prevention


  Free Subscription

Articles published in Cancer Chemother Pharmacol

Retrieve available abstracts of 17 articles:
HTML format

Single Articles

    December 2022
  1. JOHNSON S, Dhamne C, Sankaran H, Gandhi KA, et al
    A prospective, open-label, randomised, parallel design study of 4 generic formulations of intramuscular L-asparaginase in childhood precursor B-cell acute lymphoblastic leukaemia (ALL).
    Cancer Chemother Pharmacol. 2022;90:445-453.
    PubMed     Abstract available

    November 2022
  2. JAISWAL A, Jaiswal A, Williamson EA, Gelfond J, et al
    Resistance to the BCL-XL degrader DT2216 in T-cell acute lymphoblastic leukemia is rare and correlates with decreased BCL-XL proteolysis.
    Cancer Chemother Pharmacol. 2022 Nov 8. pii: 10.1007/s00280-022-04490.
    PubMed     Abstract available

    August 2022
  3. SATO H, Kobayashi T, Fujita N, Yamashita T, et al
    Safe administration and pharmacokinetic monitoring of crushed venetoclax tablets with posaconazole and clarithromycin via percutaneous endoscopic gastrostomy tube in a patient with acute myeloid leukemia.
    Cancer Chemother Pharmacol. 2022 Aug 13. pii: 10.1007/s00280-022-04460.
    PubMed     Abstract available

  4. ZHANG W, Liu J, Li Y, Guo F, et al
    A bavachinin analog, D36, induces cell death by targeting both autophagy and apoptosis pathway in acute myeloid leukemia cells.
    Cancer Chemother Pharmacol. 2022 Aug 12. pii: 10.1007/s00280-022-04462.
    PubMed     Abstract available

    June 2022
  5. LIAO LH, Chen YQ, Huang DP, Wang LN, et al
    The comparison of plasma arsenic concentration and urinary arsenic excretion during treatment with Realgar-Indigo naturalis formula and arsenic trioxide in children with acute promyelocytic leukemia.
    Cancer Chemother Pharmacol. 2022 Jun 27. pii: 10.1007/s00280-022-04449.
    PubMed     Abstract available

  6. SECHAUD R, Sinclair K, Grosch K, Ouatas T, et al
    Evaluation of drug-drug interactions between midostaurin and strong CYP3A4 inhibitors in patients with FLT-3-mutated acute myeloid leukemia (AML).
    Cancer Chemother Pharmacol. 2022 Jun 25. pii: 10.1007/s00280-022-04448.
    PubMed     Abstract available

    March 2022
  7. FUKUDA N, Akamine Y, Abumiya M, Takahashi S, et al
    Relationship between achievement of major molecular response or deep molecular response and nilotinib plasma concentration in patients with chronic myeloid leukemia receiving first-line nilotinib therapy.
    Cancer Chemother Pharmacol. 2022 Mar 22. pii: 10.1007/s00280-022-04419.
    PubMed     Abstract available

    February 2022
  8. RAMALINGAM R, Kaur H, Scott JX, Sneha LM, et al
    Evaluation of cytogenetic and molecular markers with MTX-mediated toxicity in pediatric acute lymphoblastic leukemia patients.
    Cancer Chemother Pharmacol. 2022 Feb 14. pii: 10.1007/s00280-022-04405.
    PubMed     Abstract available

    January 2022
  9. LIU J, Luo W, Chen Q, Chen X, et al
    Curcumin sensitizes response to cytarabine in acute myeloid leukemia by regulating intestinal microbiota.
    Cancer Chemother Pharmacol. 2022 Jan 23. pii: 10.1007/s00280-021-04385.
    PubMed     Abstract available

    November 2021
  10. YOSHIDA K, Fujita A, Narazaki H, Asano T, et al
    Drug resistance to nelarabine in leukemia cell lines might be caused by reduced expression of deoxycytidine kinase through epigenetic mechanisms.
    Cancer Chemother Pharmacol. 2021 Nov 26. pii: 10.1007/s00280-021-04373.
    PubMed     Abstract available

  11. TONG WH
    Comment on "Pharmacodynamics of cerebrospinal fluid asparagine after asparaginase".
    Cancer Chemother Pharmacol. 2021;88:919-920.

    October 2021
  12. PANETTA JC, Liu Y, Bottiglieri T, Arning E, et al
    Pharmacodynamics of cerebrospinal fluid asparagine after asparaginase.
    Cancer Chemother Pharmacol. 2021;88:655-664.
    PubMed     Abstract available

    September 2021
  13. CONDORELLI A, Matteo C, Leotta S, Schinina G, et al
    Venetoclax penetrates in cerebrospinal fluid of an acute myeloid leukemia patient with leptomeningeal involvement.
    Cancer Chemother Pharmacol. 2021 Sep 29. pii: 10.1007/s00280-021-04356.
    PubMed     Abstract available

    July 2021
  14. GOTO H, Yoshino Y, Ito M, Nagai J, et al
    Correction to: Aurora B kinase as a therapeutic target in acute lymphoblastic leukemia.
    Cancer Chemother Pharmacol. 2021 Jul 18. pii: 10.1007/s00280-021-04321.

    June 2021
  15. TOKSVANG LN, Andres-Jensen L, Rank CU, Niinimaki R, et al
    Maintenance therapy and risk of osteonecrosis in children and young adults with acute lymphoblastic leukemia: a NOPHO ALL2008 sub-study.
    Cancer Chemother Pharmacol. 2021 Jun 18. pii: 10.1007/s00280-021-04316.
    PubMed     Abstract available

    May 2021
  16. YOUSSEF YH, Makkeyah SM, Soliman AF, Meky NH, et al
    Influence of genetic variants in asparaginase pathway on the susceptibility to asparaginase-related toxicity and patients' outcome in childhood acute lymphoblastic leukemia.
    Cancer Chemother Pharmacol. 2021 May 7. pii: 10.1007/s00280-021-04290.
    PubMed     Abstract available

    April 2021
  17. NIELSEN SN, Toksvang LN, Grell K, Nersting J, et al
    No association between relapse hazard and thiopurine methyltransferase geno- or phenotypes in non-high risk acute lymphoblastic leukemia: a NOPHO ALL2008 sub-study.
    Cancer Chemother Pharmacol. 2021 Apr 29. pii: 10.1007/s00280-021-04281.
    PubMed     Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Leukemia is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.